Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Subcutaneous infliximab monotherapy versus subcutaneous infliximab plus immunosuppression in moderate to severe Crohn's disease
2021-000469-33Phase 3Active
- Sponsor
- Amsterdam University Medical Center
- Start
- Mar 2021
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of infliximab, mercaptopurine, azathioprine, tioguanine and methotrexate in Crohn's disease (2 arms), sponsored by Amsterdam University Medical Center. Primary endpoint: Combined corticosteroid-free clinical remission and endoscopic response at week 26. Started Mar 2021; status: active.
02
Drugs
infliximabmercaptopurineazathioprinetioguaninemethotrexate
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on 2021-000469-33.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-000469-33.